CLINICAL TRIALS PROFILE FOR SUMANIROLE

Clinical Trials for Sumanirole

Trial ID	Title	Status	Sponsor	Phase	Summary
NCT00036205 ↗	Open Label Sumanirole Study of Safety, Tolerability, and Therapeutic Response In Patients With Parkinson's Disease	Terminated	Pfizer	Phase 3	The primary objective is to assess the long term safety and tolerability of sumanirole as measured by safety labs, ECG monitoring, vital signs, and adverse event reports in subjects with Parkinson's Disease who participated in previous sumanirole studies.
NCT00036218 ↗	Study Evaluating Sumanirole for the Treatment of the Signs and Symptoms of Early Parkinson's Disease.	Completed	Pfizer	Phase 3	The primary purpose of this study is to determine whether sumanirole is effective and safe in the treatment of the signs and symptoms of early Parkinson's disease.
NCT00058838 ↗	Study Evaluating Sumanirole for the Treatment of the Signs and Symptoms of Early Parkinson's Disease	Completed	Pfizer	Phase 3	The primary purpose of this study is to determine whether sumanirole, at three different dose levels, is effective and safe in the treatment of the signs and symptoms of early Parkinson's disease

Clinical Trial Conditions for Sumanirole

Condition Name

Condition Name
Intervention	Trials
Parkinson Disease	3

Condition MeSH

Condition MeSH
Intervention	Trials
Parkinson Disease	3

Clinical Trial Locations for Sumanirole

Trials by Country

Trials by Country
Location	Trials
United States	94
Argentina	7
Mexico	5
Colombia	4
Spain	4

Trials by US State

Trials by US State
Location	Trials
Texas	3
Pennsylvania	3
North Carolina	3
New York	3
New Hampshire	3

Clinical Trial Progress for Sumanirole

Clinical Trial Phase

Clinical Trial Phase
Clinical Trial Phase	Trials
Phase 3	3

Clinical Trial Status

Clinical Trial Status
Clinical Trial Phase	Trials
Completed	2
Terminated	1

Clinical Trial Sponsors for Sumanirole

Sponsor Name

Sponsor Name
Sponsor	Trials
Pfizer	3

Sponsor Type

Sponsor Type
Sponsor	Trials
Industry	3